GGrantIndex
← Leaderboards

Bret J Rudy

Children'S Hospital Of Philadelphia

$5,647,039
Attributed
$5,647,039
Total exposure
12
Grants
1
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $681.7K · FY200507
$1M$750K$500K$250K$0
'05
'06
'07

Funding mix

By agency

NIH$5,647,039 · 12

By mechanism

U01$5,554,837 · 1
M01$92,202 · 11

Top collaborators

No co-investigators on record.

Most similar at Children'S Hospital Of Philadelphia

Same institution · by research overlap

Others in their field

Top investigators on “Hiv Infections

Research focus

Hiv InfectionsHuman SubjectClinical ResearchAdolescence (12-20)Patient Oriented ResearchAids TherapyHuman Therapy EvaluationClinical TrialsHealth BehaviorDisease /Disorder Proneness /RiskPediatric AidsHuman Immunodeficiency Virus 1Longitudinal Human StudyAids /Hiv DiagnosisHealth Care Referral /ConsultationMedical Outreach /Case FindingAids /Hiv TestDisease /Therapy DurationSubstance Abuse Related DisorderAids Education /PreventionYoung Adult Human (21-34)Antiaids AgentAidsCooperative Study

Grant awards (25)

Adolescent Medicine Trials Network for HIV/AIDS Interve*$372,712
U01 · FY2007 · HD · contact PI
Adolescent Medicine Trials Network for HIV/AIDS Interve*$215,124
U01 · FY2006 · HD · contact PI
ADOLESCENT MEDICINE TRIALS UNIT AT CHOP$646,626
U01 · FY2005 · HD
ATN 026: CD8 + T-CELL RESPONES AND ESCAPE MUTATIONS$9,433
M01 · FY2005 · RR
ATN 021: MORPHOLOGIC &METABOLIC ABNORMALITIES IN YOUNG WOMEN W/WO HIV$8,386
M01 · FY2005 · RR
PREVALENCE OF HIV-1 RESISTANCE MARKERS IN A RECENTLY INFECTED POPULATION OF ADOL$8,386
M01 · FY2005 · RR
SHORT-CYCLE THERAPY IN ADOLESCENTS WITH ESTABLISHED VIRAL SUPPRESSION HIV$7,336
M01 · FY2005 · RR
PACTG 381: ESTABLISHMENT AND MAINTENANCE OF UNDETECTABLE PLASMA HIV-1 RNA$1,573
M01 · FY2005 · RR
ADOLESCENT MEDICINE TRIALS UNIT AT CHOP$1,570,476
U01 · FY2004 · HD
PREVALENCE OF HIV-1 RESISTANCE MARKERS IN A RECENTLY INFECTED POPULATION OF ADOL$15,081
M01 · FY2004 · RR
SHORT-CYCLE THERAPY IN ADOLESCENTS WITH ESTABLISHED VIRAL SUPPRESSION$15,081
M01 · FY2004 · RR
ADOLESCENT TRIAL NETWORK FOR HIV/AIDS INTERVENTION (ATN)$10,770
M01 · FY2004 · RR
PACTG 381: Establishment and maintenance of undetectable plasma HIV-1 RNA$7,539
M01 · FY2004 · RR
PREVALENCE OF MORPHOLOGIC &METABOLIC ABNORMALITIES IN HIV INFECTED/UNAFFECTED$4,307
M01 · FY2004 · RR
STRUCTURED TX INTERRUPTION AS AN AUTOVACCINATION APPROACH TO ENHANCE HIV-1$2,155
M01 · FY2004 · RR
TYPOLOGY OF ADHERENCE IN ADOLESCENTS PHASE 1$2,155
M01 · FY2004 · RR
ADOLESCENT MEDICINE TRIALS UNIT AT CHOP$912,102
U01 · FY2003 · HD
ADOLESCENT MEDICINE TRIALS UNIT AT CHOP$723,984
U01 · FY2002 · HD
REACH--REACHING FOR EXCELLENCE IN ADOLESCENT HEALTH CARE$0
M01 · FY2002 · RR
ESTABLISH/MAINTAIN UNDETECTABLE PLASMA HIV 1 RNA$0
M01 · FY2002 · RR
ACTG 356--ZDV/3TC/NEVIRAPINE COMBINTION THERAPY IN HIV INFANTS AND CHILDREN$0
M01 · FY2002 · RR
ADOLESCENT MEDICINE TRIAL NETWORK FOR HIV/AIDS$1,113,813
U01 · FY2001 · HD
ACTG 356--ZDV/3TC/NEVIRAPINE COMBINTION THERAPY IN HIV INFANTS AND CHILDREN$0
M01 · FY2000 · RR
ESTABLISH/MAINTAIN UNDETECTABLE PLASMA HIV 1 RNA$0
M01 · FY2000 · RR
REACH--REACHING FOR EXCELLENCE IN ADOLESCENT HEALTH CARE$0
M01 · FY2000 · RR